"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”
A trial looking at intensity modulated radiotherapy (IMRT) to treat prostate cancer
This trial looked at intensity modulated radiotherapy to treat prostate cancer which was likely to spread to the lymph nodes in the pelvis. It was supported by Cancer Research UK.
More about this trial
Intensity modulated radiotherapy (IMRT) is a way of targeting the area of prostate cancer more exactly. This means that doctors are able to give a larger dose of radiotherapy to the cancer and a lower dose to surrounding healthy tissue. The aim of this is to reduce side effects of radiotherapy.
Researchers running this trial looked at several different doses of radiotherapy. Radiotherapy doses are measured in Gray (Gy). You often have radiotherapy split into several doses of a few Gray each time.
There were 5 groups in this trial, each group had slightly different doses of radiotherapy. Everyone had radiotherapy to the prostate and to the lymph nodes in the pelvic area around the prostate.
Some people had a smaller number of radiotherapy treatments, but a higher dose of radiotherapy per treatment. This is called hypofractionation, or hypofractionated radiotherapy.
The aim of this trial was to find out more about different doses of IMRT for prostate cancer.
Summary of results
This trial recruited 447 men into 5 groups. Everyone taking part had IMRT, but the number of treatments and the dose per treatment varied a bit between the groups.
The first few men who joined the trial were in group 1, and the next few were in group 2. And so on.
Radiotherapy for prostate cancer can cause side effects such as problems with the bowel and bladder. There wasn’t much difference between the number of men who were having side effects 2 years after treatment:
- between 8 and 16 out of every 100 men (8 – 16%) had bowel side effects
- between 3 and 7 out of every 100 men (3 – 7%) had bladder side effects
The research team then looked at how well the treatment had worked 5 years after joining the trial.
They looked at how many men had no signs that the cancer had started to grow again, and found it was:
- Group 1 – nearly 4 out of 10 men (38%)
- Group 2 – just over 6 out of 10 men (61%)
- Group 3 – 7 out of 10 men (70%)
- Group 4 – 8 out of 10 men (80%)
- Group 5 – nearly 8 out of 10 men (78%)
The researchers found that more than 9 out of 10 men (94%) had no signs of cancer in the lymph nodes in the pelvis.
They also looked at how many men were living 5 years after joining the trial. They found it was similar or better than men who have been treated with standard radiotherapy (not IMRT) in other trials or as standard treatment:
- Group 1 – more than 7 out of 10 men (76%)
- Group 2 – nearly 9 out of 10 men (87%)
- Group 3 – more than 8 out of 10 men (86%)
- Group 4 – just under 9 out of 10 men (89%)
- Group 5 – more than 9 out of 10 men (91%)
The research team concluded that using IMRT to treat lymph nodes in the pelvic area was safe, and didn’t cause too many side effects. The radiotherapy methods developed by the research team are now being used in other trials.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor David Dearnaley
Cancer Research UK
Institute of Cancer Research (ICR)
NIHR Clinical Research Network: Cancer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040